Ultimately, based on our analysis, S100A16 and S100A14 were validated as potential second-class drug targets for HER-positive breast cancer, PDE5A as potential first-class drug targets for colorectal cancer, and MIA as potential second-class drug targets for non-small cell lung cancer. Here, PDE5A is linked to non-small cell lung carcinoma.